Mayne Pharma Group Limited (MYX.XA)
Cboe AU · AUD
A$2.43 (-2.15%) as of
Key statistics
- EPS (TTM)
- -0.0480
- 52-week range
- 2.0200 – 6.2400
- Beta
- 1.02
- Revenue (TTM)
- 383.68M
- Profit margin
- 6.38%
- Volume
- 40.59k
About Mayne Pharma Group Limited
Mayne Pharma Group Limited, a specialty pharmaceutical company, focuses on the commercialization of women's health and dermatology pharmaceuticals in Australia, New Zealand, the United States, Canada, Europe, Asia, and internationally. It operates through three segments: Women's Health, Dermatology, and International. The company provides oral drug delivery systems, as well as contract development and manufacturing services to third party customers. It also distributes specialty pharmaceutical products in the dermatology, women's health, and infectious disease areas. The company was formerly known as Halcygen Pharmaceuticals Limited and changed its name to Mayne Pharma Group Limited in November 2010. Mayne Pharma Group Limited was incorporated in 2005 and is based in Salisbury South, Australia.
- Headquarters
- Salisbury South, SA, Australia
- Employees
- 363
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.